<DOC>
	<DOCNO>NCT00958334</DOCNO>
	<brief_summary>ZPU-003 EXT 2-year extension study ZPU-003 determine continue safety efficacy Proellex woman previously complete double-blind portion study .</brief_summary>
	<brief_title>Extension Study Proellex Women Who Have Previously Completed Study ZPU 003</brief_title>
	<detailed_description>ZPU-003 EXT 2-year extension study ZPU-003 . The purpose study determine continue safety efficacy Proellex woman previously complete double-blind portion study . The desired primary efficacy outcome change vaginal bleeding baseline 14 month 17 month study drug . The total duration study 24 month include transition time , drug interval , follow-up visit ) . It expect 16 week drug interval menses subside return 4-8 week drug interval ( ODI ) .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Completed ZPU 003 study meet inclusion/exclusion criterion study . Low high grade cervical dysplasia , determine Papanicolaou ( PAP ) smear . Pregnant breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine fibroid</keyword>
</DOC>